Growth hormone and prostate cancer: Guilty by association?

Journal of Endocrinological Investigation

Volumn 22, Issue 5 SUPPL., 1999, Pages 64-73

  Grimberg, A ^a   Cohen, P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Growth hormone; Insulin like growth factor binding proteins; Insulin like growth factor I; Prostate cancer

Indexed keywords

HUMAN GROWTH HORMONE; SOMATOMEDIN C;

ANIMAL; DISEASE MODEL; HUMAN; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; REVIEW; RISK FACTOR;

ANIMALS; DISEASE MODELS, ANIMAL; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 0032616876     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Cohen P., Peehl D.M., Stamey T.A., Wilson K.F., Clemmons D.R., Rosenfeld R.G. Elevated levels of insulin-like growth factor binding protein-2 in the serum of prostate cancer patients. J. Clin. Endocrinol. Metab. 1993, 76: 1031.
2. Kanety H., Madjar Y., Dagan Y., Levi J., Papa M.Z., Pariente C., Goldwasser B., Karasik A. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J. Clin. Endocrinol. Metab. 1993, 77: 229.
3. Ho P.J., Baxter R.C. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin. Endocrinol. 1997, 46: 333.
4. Wolk A., Mantzoros C.S., Andersson S.O., Bergstrom R., Signorello L.B., Lagiou P., Adami H.O., Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl. Cancer Inst. 1998, 90: 911.
5. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., Hennekens C.H., Pollack M. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science 1998, 279: 563.
6. Mantzoros C.S., Tzonou A., Signorello L.B., Stampfer A., Trichopoulos D., Adami H.O. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br. J. Cancer 1997, 76: 1115.
7. Mettlin C. Recent developments in the epidemiology of prostate cancer. Eur. J. Cancer 1997, 33: 340.
8. Krongrad A., Lai S., Vidal E.M. The significance of changing trends in prostate cancer incidence and mortality. Semin. Urol. Oncol. 1998, 16: 30.
9. Stephenson R.A., Stanford, J.L. Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen. World J. Urol. 1997, 15: 331.
10. Potosky A.L., Miller B.A., Albertsen P.C., Kramer B.S. The role of increasing detection in the rising incidence of prostate cancer. J. Am. Med. Assoc. 1995, 273: 548.
11. Grimberg A., Rajah R., Zhao H., Cohen P. The prostatic IGF system: new levels of complexity. In: Takano K., Hizuka N., Takahashi S.I. (Eds.), Molecular mechanisms to regulate the activities of insulin-like growth factors. Elsevier, Amsterdam, 1998, p. 205.
12. Cohen P., Peehl D.M., Bhala A., Dong G., Hintz R.L., Rosenfeld R.G. The IGF axis in prostatic disease. In: Baxter R.C., Gluckman P.D., Rosenfeld R.G. (Eds.), The IGFs and their regulatory proteins. Elsevier, Amsterdam, 1994, p. 369.
13. Cohen P., Peehl D.M., Lamson G., Rosenfeld R.G. Insulin-like growth factors (IGFs), IGF receptors and IGF binding proteins in primary cultures of prostate epithelial cells. J. Clin. Endocrinol. Metab. 1991, 73: 491.
14. Angelloz-Nicoud P., Binoux M. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology 1995, 136: 5485.
15. Figueroa J.A., Lee A.V., Jackson J.G., Yee D. Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for an IGF-II autocrine growth loop. J. Clin. Endocrinol. Metab. 1995, 80: 3476.
16. Pietrzkowski Z., Mulholland G., Gomella L., Jameson B.A., Wernicke D., Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res. 1993, 53: 1102.
17. Plymate S.R., Tennant M., Birnbaum R.S., Thrasher J.B., Chatta G., Ware J.L. The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen. J. Clin. Endocrinol. Metab. 1996, 81: 3709.
18. Tennant M.K., Thrasher J.B., Twomey P.A., Drivdahl R.H., Birnbaum R.S., Plymate S.R. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J. Clin. Endocrinol. Metab. 1996, 81: 3774.
19. Cohen P., Peehl D.M., Maker B., Liu F., Hintz R.L., Rosenfeld R.G. Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 1994, 79: 1410.
20. Figueroa J.A., De Raad S., Tadlock L., Speights V.O., Rinehart J.J. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J. Urol. 1998, 159: 1379.
21. Hampel O.Z., Kattan M.W., Yang G., Haidacher S.J., Saleh G.Y., Thompson T.C., Wheeler T.M., Marcelli M. Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study. J. Urol. 1998, 159: 2220.
22. Rajah R., Valentis B., Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates effects of transforming growth factor-beta 1 on programmed cell death through a p53- and IGF-independent mechanism. J. Biol. Chem. 1997, 272: 12181.